Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Korea FDA Rebuts Reports Of Compulsory Licensing For Roche's Tamiflu

This article was originally published in The Pink Sheet Daily

Executive Summary

Though policy would allow the government to ignore originator patents in an emergency, "Our basic stance remains unchanged for now," KFDA says; drug maker and ingredient supplier are standing by.

You may also be interested in...



Korea Moves To Cover A/H1N1 Test With National Health Insurance

SEOUL - Alarmed over the deaths of two South Koreans over the weekend infected with the A/H1N1 virus and over the rising number of people who have fallen victim to the pandemic, the government is moving to have the H1N1 test covered by the national health insurance system

South Korea's Green Cross Begins "Test Production" of Flu Vaccine

SEOUL - South Korean pharmaceutical company Green Cross recently started "test production" of its own A/H1N1 flu vaccine, after receiving a virus strain from the UK's National Institution for Biological Standards and Control and from the Centers for Disease Control and Prevention of the U.S

Korea Signs Deals With Roche, GSK For More Tamiflu, Relenza

SEOUL - Alarmed by the rising number of people infected with the H1N1 virus in neighboring Japan, and in Korea, the South Korean government has signed contracts recently to secure more of Roche's Tamiflu (oseltamivir) and GlaxoSmithKline's Relenza (zanamivir)

Topics

UsernamePublicRestriction

Register

PS142970

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel